
---------- Without TGFβ1 ----------
Beads only
IL-2/0.5 ug/ml
IL-2/5 ug/ml
IL-2m 0.5 ug/ml
IL-2m 5 ug/ml
3.61
3.68
3.09
2.45
2.16
2.17
1.90
2.13
2.50
2.25
2.19
2.54
1.93
2.12
2.42

FIG. 1A


--------- With 3 ng/ml TGFβ1 ---------
Beads only
IL-2/0.5 ug/ml
IL-2/5 ug/ml
IL-2m 0.5 ug/ml
IL-2m 5 ug/ml
13.0
11.3
14.0
57.3
54.2
52.4
52.4
51.7
51.3
45.7
46.8
44.2
58.8
52.4
60.2

FIG. 1B



FIG. 2A



FIG. 2B


IL-2 mutein
10 μg s.c. 2x in a week
analysis of blood pre-Tx
Normal B6
8.81%
8.46%
45.5%
56.2%
47.0%
48.7%
49.5%
IL-2A
Foxp3
CD4

FIG. 3


BALB/c->C57BL/6
Only x2 injections of IL-2 pre-Tx
A ~50% Tregs
C ~30%
D ~20%
~normal by d 10 post-Tx
plus 0.5 mg/kg/d RPM 14 d (Aizet)
RPM
IL2 C+RPM
IL2 D+RPM
IL2A+RPM
IL2
Probability of survival
100
50
0
0
50
100
150
Time (Day)

FIG. 4


IL2C alone
Control
IL2C 10ug/mouse/2x/w/3 weeks
Probability of Survival
100
50
0
0
10
20
30
40
50
Time (Day)

FIG. 5


C3H HTX at 100 days
RPM
IL2C (80 day)+RPM
IL2C (21 day)+RPM
C3H
0.5 mg/kg/d RPM 14 d (Alzet)
10 µg i.p. x2/wk IL-2C from Tx
IL-2C dosing stopped at day 21 or continued to day 80 post-Tx
Probability of Survival
100
50
0
0
50
100
Days elapsed

FIG. 6A


rejected
Foxp3
CD4
33.7
60.0
62.2
60.3

FIG. 6B

3 weeks of IL-2C &
14 d low-dose RPM
N = 5/group, H&E, x200



>110 d continued acceptance of BALB/c cardiac allografts

Acute rejection of C3H cardiac allografts within 8-9 d

FIG. 7